Sleep Initiation and Maintenance Disorders
Sleep
Sleep, REM
Sleep Disorders
Sleep Apnea, Obstructive
Sleep Apnea Syndromes
Polysomnography
Bipolar Disorder
Fatal familial insomnia: a new Austrian family. (1/1096)
We present clinical, pathological and molecular features of the first Austrian family with fatal familial insomnia. Detailed clinical data are available in five patients and autopsy in four patients. Age at onset of disease ranged between 20 and 60 years, and disease duration between 8 and 20 months. Severe loss of weight was an early symptom in all five patients. Four patients developed insomnia and/or autonomic dysfunction, and all five patients developed motor abnormalities. Analysis of the prion protein (PrP) gene revealed the codon 178 point mutation and methionine homozygosity at position 129. In all brains, neuropathology showed widespread cortical astrogliosis, widespread brainstem nuclei and tract degeneration, and olivary 'pseudohypertrophy' with vacuolated neurons, in addition to neuropathological features described previously, such as thalamic and olivary degeneration. Western blotting of one brain and immunocytochemistry in four brains revealed quantitative and regional dissociation between PrP(res)(the protease resistant form of PrP) deposition and histopathology. In the cerebellar cortex of one patient, PrP(res) deposits were prominent in the molecular layer and displayed a peculiar patchy and strip-like pattern with perpendicular orientation to the surface. In another patient, a single vacuolated neuron in the inferior olivary nuclei contained prominent intravacuolar granular PrP(res) deposits, resembling changes of brainstem neurons in bovine spongiform encephalopathy. (+info)Ethanol as a hypnotic in insomniacs: self administration and effects on sleep and mood. (2/1096)
The purpose of this study was to assess the effects of low ethanol doses on sleep and mood and to assess its reinforcing effects used as a hypnotic. Twenty healthy adults, aged 21-45 yrs, all moderate social drinkers, were studied: eleven subjects had insomnia and nine were normal sleepers, as documented by clinical polysomnography. On two sampling nights each, ethanol (0.5 g/kg) or placebo was administered before sleep in color-coded cups presented in three doses (0.2, 0.2, and 0.1 g/kg) separated by 15 min. On three subsequent nights subjects chose their preferred presleep beverage (0.2 g/kg ethanol or placebo) based on cup color and were given an opportunity for 3 additional refills (0.2 g/kg each) of the chosen beverage at 15 min intervals, yielding a total possible dose of 0.8 g/kg. Insomniacs chose ethanol 67% of nights and normals 22%. Insomniacs chose significantly more ethanol refills than normals for an average nightly dose of 0.45 g/kg and normals took significantly more placebo refills. On the sampling nights 0.5 g/kg ethanol reduced REM sleep for both groups for the 8-hr sleep period and in insomniacs increased stage 3-4 sleep and reduced stage 1 sleep during the first half of the night to the level seen in the normals. Other sleep variables were not altered in either group or halves of the night. Presleep improvements in the Profile of Mood States tension and concentration factors were also associated with ethanol administration. Thus, acutely, both sleep and mood effects appear to be associated with the reinforcing effects of ethanol as a hypnotic for insomniacs. (+info)Prevalence of insomnia: a survey of the enrollees at five managed care organizations. (3/1096)
The purpose of the study was to assess the prevalence of and factors associated with insomnia among enrollees of managed care organizations (MCOs). A survey was distributed either by mail or during a clinic visit to 7,500 enrollees of five MCOs in the United States. The survey included a sleep questionnaire, demographic questions, and questions about medical encounters and prescription drug use. Three levels of insomnia (none; level I--difficulty initiating or maintaining sleep; level II--insomnia with daytime dysfunction) were defined from the responses. Comorbidities were determined by proxy from prescription drug use reported by respondents. A total of 3,447 survey responses were received, yielding a response rate of 46%. Level I and level II insomnia was reported by 13.5% and 32.5% of the respondents, respectively. Level II insomnia increased with decreasing education, income, and age and was more prevalent in women and non-Caucasians. Insomnia was significantly correlated with all daytime sleepiness and most nighttime disturbances factors. Fifty-two percent of all respondents reported at least one comorbid condition. Respondents with multiple comorbidities reported level II insomnia more frequently than those with no comorbidities. Only 0.9% of clinic visitors were seeing a physician specifically for sleep problems. Of those with level I and level II insomnia, only 5.5% and 11.6%, respectively, were taking prescription medications specifically for sleep problems; 11.2% and 21.4%, respectively, were taking over-the-counter medications for sleep. Insomnia occurs in MCO enrollees at rates comparable to those found in the general population. However, few patients with insomnia are actually being treated for their condition. Proper evaluation, diagnosis, and treatment of insomnia are warranted. (+info)Insomnia. (4/1096)
Insomnia is a common complaint with potentially significant medical and psychologic complications. In some cases insomnia presents as a symptom of another underlying medical, psychiatric or environmental condition. In these cases, management of insomnia depends on accurate diagnosis and successful treatment of the underlying condition. In other cases, insomnia is a primary disorder requiring direct treatment. Pharmacologic treatments include nonprescription medications, sedating tricyclic antidepressants, benzodiazepines and related drugs. Behavior management methods that may be administered in the office setting include stimulus control therapy, sleep restriction therapy and sleep hygiene education. Although prescription medications and behavior therapy have similar short-term efficacy, behavior interventions are recommended as the first line of treatment for primary insomnia because of their greater safety and long-term efficacy. (+info)Insomnia: assessment and management in primary care. National Heart, Lung, and Blood Institute Working Group on Insomnia. (5/1096)
Patients with insomnia may experience one or more of the following problems: difficulty falling asleep, difficulty maintaining sleep, waking up too early in the morning and nonrefreshing sleep. In addition, daytime consequences such as fatigue, lack of energy, difficulty concentrating and irritability are often present. Approximately 10 percent of adults experience persistent insomnia, although most patients do not mention it during routine office visits. Asking sleep-related questions during the general review of systems and asking patients with sleep complaints to keep a sleep diary are helpful approaches in detecting insomnia. Behavior and pharmacologic therapies are used in treating insomnia. Behavior approaches take a few weeks to improve sleep but continue to provide relief even after training sessions have ended. Hypnotic medications are safe and effective in inducing, maintaining and consolidating sleep. Effective treatment of insomnia may improve the quality of life for many patients. (+info)Sleep and serotonin: an unfinished story. (6/1096)
Serotonin (5-HT) was first believed to be a true neuromodulator of sleep because the destruction of 5-HT neurons of the raphe system or the inhibition of 5-HT synthesis with p-chlorophenylalanine induced a severe insomnia which could be reversed by restoring 5-HT synthesis. However the demonstration that the electrical activity of 5-HT perikarya and the release of 5-HT are increased during waking and decreased during sleep was in direct contradiction to this hypothesis. More recent experiments suggest that the release of 5-HT during waking may initiate a cascade of genomic events in some hypnogenic neurons located in the preoptic area. Thus, when 5-HT is released during waking, it leads to an homeostatic regulation of slow-wave sleep. (+info)Chronic insomnia: a practical review. (7/1096)
Insomnia has numerous, often concurrent etiologies, including medical conditions, medications, psychiatric disorders and poor sleep hygiene. In the elderly, insomnia is complex and often difficult to relieve because the physiologic parameters of sleep normally change with age. In most cases, however, a practical management approach is to first consider depression, medications, or both, as potential causes. Sleep apnea also should be considered in the differential assessment. Regardless of the cause of insomnia, most patients benefit from behavioral approaches that focus on good sleep habits. Exposure to bright light at appropriate times can help realign the circadian rhythm in patients whose sleep-wake cycle has shifted to undesirable times. Periodic limb movements during sleep are very common in the elderly and may merit treatment if the movements cause frequent arousals from sleep. When medication is deemed necessary for relief of insomnia, a low-dose sedating antidepressant or a nonbenzodiazepine anxiolytic may offer advantages over traditional sedative-hypnotics. Longterm use of long-acting benzodiazepines should, in particular, be avoided. Melatonin may be helpful when insomnia is related to shift work and jet lag; however, its use remains controversial. (+info)Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. (8/1096)
Adverse events were analyzed in 94 normal donors who underwent PBSC harvest with G-CSF. The median dose of G-CSF was 9.7 microg/kg/day (range, 2.0-16.7), and the duration of administration was 4-6 days. Frequent symptoms were bone pain (71%), general fatigue (33%), headache (28%), insomnia (14%), anorexia (11%), nausea and/or vomiting (11%). One donor (1%) developed grade 3 toxicity bone pain (WHO criteria). WBC counts and ANC increased during G-CSF administration. After leukapheresis, three donors (3%) developed grade 3 toxicity neutropenia. Platelet counts decreased after leukapheresis. Three donors (3%) developed grade 3 thrombocytopenia. The means of both ALP and LDH increased approximately 1.9-fold compared with pretreatment levels. In one pediatric donor (1%), ALP was elevated to the grade 3 toxicity level. From multivariate analysis, the incidence of bone pain increased when G-CSF was given at a dose of 8.8 microg/kg/day or more, headaches were frequent in donors younger than 35 years, and the incidence of nausea and/or vomiting was high in female donors. The peak levels of WBC counts and ANC and post-treatment level of LDH increased in correspondence with the escalation of G-CSF dose. All adverse events normalized on follow-up evaluation. In conclusion, although PBSC harvest for normal donors is acceptable, care must be taken for all donors in terms of their sex and age as well as the G-CSF dose. We recommend less than 8.8 microg/kg/day as the G-CSF dose for PBSC mobilization in normal donors. (+info)Sleep initiation and maintenance disorders are a category of sleep disorders that involve difficulty falling asleep and staying asleep throughout the night. This category includes:
1. Insomnia disorder: A persistent difficulty in initiating or maintaining sleep, or early morning awakening, despite adequate opportunity and circumstances for sleep, which causes clinically significant distress or impairment.
2. Narcolepsy: A chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by strong emotions), hypnagogic hallucinations (vivid, dream-like experiences that occur while falling asleep) and sleep paralysis (temporary inability to move or speak while falling asleep or waking up).
3. Breathing-related sleep disorders: A group of disorders that involve abnormal breathing patterns during sleep, such as obstructive sleep apnea and central sleep apnea, which can lead to difficulty initiating and maintaining sleep.
4. Circadian rhythm sleep-wake disorders: A group of disorders that involve a misalignment between the individual's internal circadian rhythm and the external environment, leading to difficulty falling asleep and staying asleep at desired times.
5. Parasomnias: A group of disorders that involve abnormal behaviors or experiences during sleep, such as sleepwalking, night terrors, and REM sleep behavior disorder, which can disrupt sleep initiation and maintenance.
These disorders can have significant impacts on an individual's quality of life, daytime functioning, and overall health, and should be evaluated and managed by a healthcare professional with expertise in sleep medicine.
Sleep is a complex physiological process characterized by altered consciousness, relatively inhibited sensory activity, reduced voluntary muscle activity, and decreased interaction with the environment. It's typically associated with specific stages that can be identified through electroencephalography (EEG) patterns. These stages include rapid eye movement (REM) sleep, associated with dreaming, and non-rapid eye movement (NREM) sleep, which is further divided into three stages.
Sleep serves a variety of functions, including restoration and strengthening of the immune system, support for growth and development in children and adolescents, consolidation of memory, learning, and emotional regulation. The lack of sufficient sleep or poor quality sleep can lead to significant health problems, such as obesity, diabetes, cardiovascular disease, and even cognitive decline.
The American Academy of Sleep Medicine (AASM) defines sleep as "a period of daily recurring natural rest during which consciousness is suspended and metabolic processes are reduced." However, it's important to note that the exact mechanisms and purposes of sleep are still being researched and debated among scientists.
REM sleep, or Rapid Eye Movement sleep, is a stage of sleep characterized by rapid eye movements, low muscle tone, and active brain activity. It is one of the two main types of sleep along with non-REM sleep and is marked by vivid dreaming, increased brain metabolism, and altered brain wave patterns. REM sleep is often referred to as "paradoxical sleep" because of the seemingly contradictory nature of its characteristics - an active brain in a state of relaxation. It is thought to play a role in memory consolidation, learning, and mood regulation. A typical night's sleep cycle includes several episodes of REM sleep, with each episode becoming longer as the night progresses.
Sleep disorders are a group of conditions that affect the ability to sleep well on a regular basis. They can include problems with falling asleep, staying asleep, or waking up too early in the morning. These disorders can be caused by various factors such as stress, anxiety, depression, medical conditions, or substance abuse.
The American Academy of Sleep Medicine (AASM) recognizes over 80 distinct sleep disorders, which are categorized into the following major groups:
1. Insomnia - difficulty falling asleep or staying asleep.
2. Sleep-related breathing disorders - abnormal breathing during sleep such as obstructive sleep apnea.
3. Central disorders of hypersomnolence - excessive daytime sleepiness, including narcolepsy.
4. Circadian rhythm sleep-wake disorders - disruption of the internal body clock that regulates the sleep-wake cycle.
5. Parasomnias - abnormal behaviors during sleep such as sleepwalking or night terrors.
6. Sleep-related movement disorders - repetitive movements during sleep such as restless legs syndrome.
7. Isolated symptoms and normal variants - brief and occasional symptoms that do not warrant a specific diagnosis.
Sleep disorders can have significant impacts on an individual's quality of life, productivity, and overall health. If you suspect that you may have a sleep disorder, it is recommended to consult with a healthcare professional or a sleep specialist for proper evaluation and treatment.
Obstructive Sleep Apnea (OSA) is a sleep-related breathing disorder that occurs when the upper airway becomes partially or completely blocked during sleep, leading to pauses in breathing or shallow breaths. These episodes, known as apneas or hypopneas, can last for 10 seconds or longer and may occur multiple times throughout the night, disrupting normal sleep patterns and causing oxygen levels in the blood to drop.
The obstruction in OSA is typically caused by the relaxation of the muscles in the back of the throat during sleep, which allows the soft tissues to collapse and block the airway. This can result in snoring, choking, gasping for air, or awakening from sleep with a start.
Contributing factors to OSA may include obesity, large neck circumference, enlarged tonsils or adenoids, alcohol consumption, smoking, and use of sedatives or muscle relaxants. Untreated OSA can lead to serious health consequences such as high blood pressure, heart disease, stroke, diabetes, and cognitive impairment. Treatment options for OSA include lifestyle changes, oral appliances, positive airway pressure therapy, and surgery.
Sleep apnea syndromes refer to a group of disorders characterized by abnormal breathing patterns during sleep. These patterns can result in repeated pauses in breathing (apneas) or shallow breaths (hypopneas), causing interruptions in sleep and decreased oxygen supply to the body. There are three main types of sleep apnea syndromes:
1. Obstructive Sleep Apnea (OSA): This is the most common form, caused by the collapse or obstruction of the upper airway during sleep, often due to relaxation of the muscles in the throat and tongue.
2. Central Sleep Apnea (CSA): This type is less common and results from the brain's failure to send proper signals to the breathing muscles. It can be associated with conditions such as heart failure, stroke, or certain medications.
3. Complex/Mixed Sleep Apnea: In some cases, a person may experience both obstructive and central sleep apnea symptoms, known as complex or mixed sleep apnea.
Symptoms of sleep apnea syndromes can include loud snoring, excessive daytime sleepiness, fatigue, morning headaches, difficulty concentrating, and mood changes. Diagnosis typically involves a sleep study (polysomnography) to monitor breathing patterns, heart rate, brain activity, and other physiological factors during sleep. Treatment options may include lifestyle modifications, oral appliances, positive airway pressure therapy, or even surgery in severe cases.
Polysomnography (PSG) is a comprehensive sleep study that monitors various body functions during sleep, including brain activity, eye movement, muscle tone, heart rate, respirations, and oxygen levels. It is typically conducted in a sleep laboratory under the supervision of a trained technologist. The data collected during PSG is used to diagnose and manage various sleep disorders such as sleep-related breathing disorders (e.g., sleep apnea), movement disorders (e.g., periodic limb movement disorder), parasomnias, and narcolepsy.
The study usually involves the attachment of electrodes to different parts of the body, such as the scalp, face, chest, and legs, to record electrical signals from the brain, eye movements, muscle activity, and heartbeats. Additionally, sensors may be placed on or near the nose and mouth to measure airflow, and a belt may be worn around the chest and abdomen to monitor breathing efforts. Oxygen levels are also monitored through a sensor attached to the finger or ear.
Polysomnography is often recommended when a sleep disorder is suspected based on symptoms or medical history, and other diagnostic tests have been inconclusive. The results of the study can help guide treatment decisions and improve overall sleep health.
Bipolar disorder, also known as manic-depressive illness, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). When you become depressed, you may feel sad or hopeless and lose interest or pleasure in most activities. When your mood shifts to mania or hypomania (a less severe form of mania), you may feel euphoric, full of energy, or unusually irritable. These mood swings can significantly affect your job, school, relationships, and overall quality of life.
Bipolar disorder is typically characterized by the presence of one or more manic or hypomanic episodes, often accompanied by depressive episodes. The episodes may be separated by periods of normal mood, but in some cases, a person may experience rapid cycling between mania and depression.
There are several types of bipolar disorder, including:
* Bipolar I Disorder: This type is characterized by the occurrence of at least one manic episode, which may be preceded or followed by hypomanic or major depressive episodes.
* Bipolar II Disorder: This type involves the presence of at least one major depressive episode and at least one hypomanic episode, but no manic episodes.
* Cyclothymic Disorder: This type is characterized by numerous periods of hypomania and depression that are not severe enough to meet the criteria for a full manic or depressive episode.
* Other Specified and Unspecified Bipolar and Related Disorders: These categories include bipolar disorders that do not fit the criteria for any of the other types.
The exact cause of bipolar disorder is unknown, but it appears to be related to a combination of genetic, environmental, and neurochemical factors. Treatment typically involves a combination of medication, psychotherapy, and lifestyle changes to help manage symptoms and prevent relapses.
Wakefulness is a state of consciousness in which an individual is alert and aware of their surroundings. It is characterized by the ability to perceive, process, and respond to stimuli in a purposeful manner. In a medical context, wakefulness is often assessed using measures such as the electroencephalogram (EEG) to evaluate brain activity patterns associated with consciousness.
Wakefulness is regulated by several interconnected neural networks that promote arousal and attention. These networks include the ascending reticular activating system (ARAS), which consists of a group of neurons located in the brainstem that project to the thalamus and cerebral cortex, as well as other regions involved in regulating arousal and attention, such as the basal forebrain and hypothalamus.
Disorders of wakefulness can result from various underlying conditions, including neurological disorders, sleep disorders, medication side effects, or other medical conditions that affect brain function. Examples of such disorders include narcolepsy, insomnia, hypersomnia, and various forms of encephalopathy or brain injury.